Significant - Monitor Closely. Talk to your doctor if you breastfeed your baby.
Patients should be advised to inform their prescriber of their use of CoQ Worsening of heart failure has been reported in patients with impairment of ventricular function. Major Diltiazem has been shown to increase encainide AUC and half-life.
Patients receiving intravenous lacosamide should be closely monitored due to the potential for profound bradycardia and AV block during coadministration. Diltiazem may increase plasma concentrations of quetiapine through CYP3A4 inhibition.
In some cases, they may not be available in every strength or form as the brand. Acute MI and pulmonary congestion IV: Crizotinib and diltiazem are both CYP3A substrates and moderate inhibitors. Patients receiving estrogens should be monitored for an increase in adverse events. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.
What is diltiazem?
Major Avoid coadministration of olaparib with diltiazem and consider alternative agents with less CYP3A4 inhibition due to increased olaparib exposure. Discuss the use of grapefruit products with your doctor.
Although concomitant use of moderate CYP3A4 inhibitors with lomitapide has not been studied, a significant increase in lomitapide exposure is likely during concurrent use. Allergy warning Diltiazem can cause a severe allergic reaction. Combining the drugs in clinical practice may require close monitoring to ensure proper therapeutic responses; monitor patients for symptoms and signs of toxicity, such as myelosuppression and peripheral neuropathy.
Increased plasma concentrations of both drugs may occur. Diltiazem may be only part of a complete program of treatment that also includes diet, exercise, and other medications. Free E-newsletter Subscribe to Housecall Our general interest e-newsletter keeps you up to date on a wide variety of health topics.
It is possible that additive reductions in blood pressure may be seen when fish oils are used in a patient already taking antihypertensive agents.
If used concurrently, close clinical monitoring with appropriate reductions are advise. Controlled studies in pregnant women show no evidence of fetal risk. When possible, avoid coadministration of these drugs and consider alternative therapy. If these drugs are administered together, monitor patients for adverse effects, such as hypotension, headache, fatigue, nausea, and diarrhea. Take diltiazem exactly as prescribed by your doctor.
Most commonly, these are "non-preferred" brand drugs. An overdose of diltiazem can be fatal. In geriatric versus younger adult subjects, the half-life of diltiazem is prolonged and clearance is decreased, with potential increase in risk for drug accumulation and toxicity.